Zealand Pharma Shares Surge Following Positive Analyst Ratings

Zealand Pharma A/S (OTCMKTS:ZLDPF) experienced a significant increase in its share price before the market opened on Thursday. The stock, which closed at $63.00 the previous day, opened at $67.90, reflecting strong investor interest and positive sentiment from analysts.

This upward movement in share price comes on the heels of recent upgrades and assessments from various equities research analysts. Notably, BTIG Research upgraded Zealand Pharma to a “strong-buy” rating on November 28, 2023. Meanwhile, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating for the stock in a report released on December 16, 2023. Currently, five analysts have assigned a “strong buy” rating to the company, while two have given it a “hold” rating. According to data from MarketBeat, the stock now holds an average rating of “buy.”

Recent Earnings Report and Analyst Predictions

On November 13, 2023, Zealand Pharma announced its quarterly earnings results, revealing an earnings per share (EPS) of ($0.90). This figure surpassed analysts’ consensus estimates of ($1.11) by $0.21. The company reported a remarkable return on equity of 55.76% and a net margin of 71.79%. Revenue for the quarter was reported at $7.76 million, significantly exceeding analyst forecasts of $4.54 million. Looking ahead, research analysts predict that Zealand Pharma will post an EPS of ($2.19) for the current fiscal year.

Zealand Pharma A/S, based in Denmark, specializes in the discovery, design, and development of peptide-based therapeutics. The company employs proprietary peptide engineering platforms to address metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Their approach focuses on optimizing stability, selectivity, and dosing profiles of therapeutic candidates, aiming to enhance patient outcomes in areas where existing treatments are limited.

Among the most advanced products in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

As the market responds to analyst ratings and earnings reports, Zealand Pharma A/S continues to attract attention from investors and analysts alike. The company’s strategic focus on innovative peptide therapies positions it well for future growth in a competitive biopharmaceutical landscape.